A multi-centre, double-blind, randomised, placebo-controlled trial, of oral anticoagulation with apixaban in participants with Systemic Sclerosis-related Pulmonary Arterial Hypertension, measuring time to clinical worsening of Pulmonary Arterial Hypertension.
Phase of Trial: Phase III
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Apixaban (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms SPHInX
- 27 Apr 2017 Planned End Date changed from 4 Dec 2017 to 31 Dec 2021.
- 21 May 2015 Status changed from not yet recruiting to recruiting as per Australian New Zealand Clinical Trials Registry.
- 02 Jul 2014 New trial record